Novartis Cosentyx® positive 16-week PREVENT results advance potential new indication for patients with axial spondyloarthritis

    NEXT STORY
    Nurse Call Systems Market to Reach USD 2.79 Billion by 2026; Rising Incidence of Chronic Diseases to Propel Market, says Fortune Business Insights
    PREV STORY
    Aclaris Therapeutics’ A-101 45% Topical Solution Meets Primary and All Secondary Efficacy Endpoints in Pivotal Phase 3 Trial for the Treatment of Common Warts (THWART-2)
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    PositiveID Corporation Announces Lawrence Livermore National Laboratory Evaluation of PositiveID’s FireflyDX

    DELRAY BEACH, Fla., Jan. 22, 2018 (GLOBE NEWSWIRE) -- PositiveID Corporation (OTC:PSID), a life ...

    author_avatar
    NASDAQ Market News

    Roche launches laboratory SARS-CoV-2 antigen test to support high-volume testing of suspected COVID-19 patients

    author_avatar
    NASDAQ Market News

    ContraFect Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update

    author_avatar
    NASDAQ Market News